Moderna and Recipharm (STO: RECI-B) reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 vaccine supply outside of the U.S. The activity will be performed in Recipharm’s drug product manufacturing facility located in France. Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it is anticipated that supply will commence in early 2021.
“We are making important progress in the development of the Moderna COVID-19 vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Moderna’s Nicolas Chornet, senior vice president, international manufacturing. “We look forward to their support in the delivery of our vaccine to market.”
“This is a material and strategically important agreement for us, and we are delighted to be working with Moderna on such a vital project to support the long-term fight against COVID-19,” added Thomas Eldered, CEO of Recipharm. “Our preparations are already well underway with the hiring of new staff and investment in the facility to enable us to meet the challenging timelines.”
